1. Iron Deficiency in Heart Failure

3. Introduction

4. Challenges in the Diagnosis of ID

5. ID and Anemia Are Distinct Comorbidities of HF

6. Challenges in the Diagnosis of ID (Cont.)

7. Diagnosis of ID: Available by Routine Laboratory Tests

8. Blood Tests Used to Diagnose ID

9. ID Definitions Used in RCTs: Consistency Across Various Studies

10. Blood Tests Used to Diagnose ID (Cont.)

11. Algorithm for the Screening and Diagnosis of ID in Patients With HF

12. ID With or Without Anemia

13. ID Is Common in Patients With HF Regardless of the Presence of Anemia

14. Algorithm for the Screening and Diagnosis of ID in Patients With HF (Cont.)

15. Recommendations on the Screening and Diagnosis of ID in Patients With HF

16. Strategies to Improve the Identification and Diagnosis of ID in Patients With HF

17. Strategies to Improve the Identification and Diagnosis of ID in Patients With HF (Cont.)

18. ID in Patients With HFpEF

19. ESC Guidelines for the Diagnosis and Treatment of HF

20. FAIR-HF: Co-Primary Endpoints

21. IV FCM in Patients With ID and HF According to the Presence of Anemia at Baseline

22. CONFIRM-HF: Primary Endpoint

23. Efficacy of FCM Stratified According to the Presence of Anemia

24. CONFIRM-HF: Time to First Hospitalization Due to Worsening HF

25. Effects of FCM on ID in HF: Meta-Analysis

26. Recurrent Event Analysis: CV Hospitalizations and CV Mortality

27. Meta-Analysis: Time to First Event Outcomes

28. EFFECT-HF

29. EFFECT-HF: Primary Endpoint Change in Peak VO2

30. Overall FCM Is Safe and Well Tolerated

31. High-Dose Oral Iron in HFrEF: Results of the IRONOUT HF Trial

32. Use of Oral Iron in Clinical Practice

33. Select Ongoing Trials With FCM

34. Summary and Conclusions

35. Abbreviations

36. Abbreviations (cont)

37. Abbreviations (cont)